We model, track, store and replicate large biological data sets like DNA and proteins.

Analysis and interpretation of such massive biological datasets enables us to make sense of complex genomics, structural & computational biology, disease control, drug discovery, precision medicine and plant biology

Our microfluidic cell-culture technology creates human-relevant patient models by integrating digital twins and computational models with organ-on-a-chip platforms lined with living human cells, enabling the simulation and study of human biology, disease progression and prediction of drug efficacy, treatment interactions, therapeutic interventions and potential clinical outcomes.

•We treat genome as programmable biological software and gene-regulatory networks as the control architecture or operating system that governs cellular state and function. In this way, we can precisely manipulate genetic circuits, transcriptional programs and epigenetic states, making it possible to reprogram cells—altering their specialised identity, behaviour and function.

The brain is an electrochemical information-processing system. Neurons communicate by generating electrical activity and releasing neurotransmitters. When groups or populations of neurons perform an action—moving your hand, seeing an object, speaking, remembering something—their activity produces measurable patterns.

We measure those patterns and infer the brain’s actions. We then record the activity, extract and map relevant features, decode and output the intention

Our focus is a bidirectional neural interface - translating biological signals into computational intelligence—and computational intelligence back into precise biological stimuli —creating a closed loop operating interface between biology and silicon: a layer that allows brain-computer monitoring, understanding, manipulation, control and augmentation with unprecedented precision

We intend to harness the potential of this technology to advance humanity forward in ways never imagined possible

We are in the early stages of growing functional replacement human organs.

The shortage of transplantable human organs for people with organ failure spells that current demand is exceeding supply. And for the few who receive organ transplants, most remain on lifelong immunosuppressive medications and monitoring. A translation of high healthcare costs and a poor quality of life

We want to change that, a replacement organ developed from a patient's own cells or programmed stem cells guarantees immune compatibility and a competitive quality of life